New publication on quality control and primo-diagnosis of transurethral bladder resections with full-field OCT
Montagne P, Ducesne I, Anract J, et al. Quality control and primo-diagnosis of transurethral bladder resections with full-field OCT. Proc. SPIE 10038 – 1003805 (2017). doi:10.1117/12.2250313.
Transurethral resections are commonly used for bladder cancer diagnosis, treatment and follow-up. Cancer staging relies largely on the analysis of muscle in the resections; however, muscle presence is uncertain at the time of the resection. An extemporaneous quality control tool would be of great use to certify the presence of muscle in the resection, and potentially formulate a primo-diagnosis, in order to ensure optimum patient care. Full-field optical coherence tomography (FFOCT) offers a fast and non-destructive method of obtaining images of biological tissues at ultrahigh resolution (1μm in all 3 directions), approaching traditional histological sections. This study aimed to evaluate the potential of FFOCT for the quality control and the primo-diagnosis of transurethral bladder resections. Over 70 transurethral bladder resections were imaged with FFOCT within minutes, shortly after excision, and before histological preparation. Side-by-side comparison with histology allowed to establish reading criteria for the presence of muscle and cancer in particular. Images of 24 specimens were read blindly by three non-pathologists readers: two resident urologists and a junior bio-medical engineer, who were asked to notify the presence of muscle and tumor. Results showed that after appropriate training, 96% accuracy could be obtained on both tumour and muscle detection. FFOCT is a fast and nondestructive imaging technique that provides analysis results concordant with histology. Its implementation as a quality control and primo-diagnosis tool for transurethral bladder resections in the urology suite is feasible and lets envision high value for the patient.
Meet LLTech at Agora Biotech investment event – February 22nd
The LLTech team and advisors will be present on February 22nd for the Agora Biotech Funding event.
The team will showcase the product, present the company and the investment opportunity.
For further information and request an invitation please register at www.biotech-agora.com
Biotech Agora a pour vocation de faire découvrir aux investisseurs des sociétés dans le domaine des Biotechs et des Sciences de la Vie qui offrent des innovations de rupture.
Biotech Agora met en lumière des sociétés de pointe, cotées et non cotées, et contribue au financement de l’innovation en favorisant les rencontres entre dirigeants et investisseurs.
LLTech at Photonics West 2017 – San Francisco 28 January – 2 February 2017
In BiOS, LLTech will present the latest clinical results and developments of the Light-CT Scanner. More details will be given during the following talks:
– Quality control and primo-diagnosis of transurethral bladder resections with full-field OCT, 28 January, 10:40 – 11:00 AM
– Skin cancer margin analysis within minutes with FFOCT, 28 January, 11:10 – 11:30 AM
– Non-contact full-field optical coherence tomography: a novel tool for in vivo imaging of the human cornea, 29 January, 1:45 – 2:00 PM
– Pancreatic cancer diagnosis based on full field OCT and dynamic full field OCT, 30 January, 10:40 – 11:00 AM
– Extracting relevant information for cancer diagnosis from dynamic full field OCT through image processing and learning, 31 January, 4:45 – 5:00 PM
Real-time analysis of colorectal polyps during coloscopy
The LLTech device was used this week under real coloscopy conditions at Cochin Hospital, Paris. Excised polyps were imaged within minutes by FFOCT in the coloscopy room, and the images transmitted to the pathologist office through the hospital network. The pathologist could thus give a feedback to the endoscopist during the coloscopy on the malignancy of the polyp.
Note: this experiment was conducted under a research study, which did not alter the patient management.
New publication on FFOCT imaging of humanized orthotopic model of hepatocellular carcinoma in immunodeficient mice
Multimodal imaging of a humanized orthotopic model of hepatocellular carcinoma in immunodeficient mice
Wu T, Heuillard E, Lindner V, et al. Multimodal imaging of a humanized orthotopic model of hepatocellular carcinoma in immunodeficient mice. Scientific Reports. 2016;6:35230. doi:10.1038/srep35230.
The development of multimodal strategies for the treatment of hepatocellular carcinoma requires tractable animal models allowing for advanced in vivo imaging. Here, we characterize an orthotopic hepatocellular carcinoma model based on the injection of luciferase-expressing human hepatoma Huh-7 (Huh-7-Luc) cells in immunodeficient mice. Luciferase allows for an easy repeated monitoring of tumor growth by in vivo bioluminescence. The intrahepatic injection was more efficient than intrasplenic or intraportal injection in terms of survival, rate of orthotopic engraftment, and easiness. A positive correlation between luciferase activity and tumor size, evaluated by Magnetic Resonance Imaging, allowed to define the endpoint value for animal experimentation with this model. Response to standard of care, sorafenib or doxorubicin, were similar to those previously reported in the literature, with however a strong toxicity of doxorubicin. Tumor vascularization was visible by histology seven days after Huh-7-Luc transplantation and robustly developed at day 14 and day 21. The model was used to explore different imaging modalities, including microtomography, probe-based confocal laser endomicroscopy, full-field optical coherence tomography, and ultrasound imaging. Tumor engraftment was similar after echo-guided intrahepatic injection as after laparotomy. Collectively, this orthotopic hepatocellular carcinoma model enables the in vivo evaluation of chemotherapeutic and surgical approaches using multimodal imaging.